A Comparative Study on Wound Healing with Topical Phenytoin 50mg/ml And Betadine 10% As Dressing Agents in Diabetic Foot Ulcers
DOI:
https://doi.org/10.63682/jns.v14i32S.8485Keywords:
diabetic foot ulcer, phenytoin, betadine, wound healing, topical therapyAbstract
Background: Diabetic foot ulcers represent a significant clinical challenge with substantial morbidity and healthcare burden. Various topical agents have been employed to enhance wound healing, with phenytoin and betadine showing promising therapeutic potential. This study compared the efficacy of topical phenytoin 50mg/ml versus betadine 10% in promoting healing of diabetic foot ulcers.
Methods: A prospective comparative study was conducted involving 120 patients with diabetic foot ulcers, randomized into two groups of 60 patients each. Group A received topical phenytoin 50mg/ml dressing, while Group B received betadine 10% dressing. Primary outcomes included time to complete healing, granulation tissue formation, and epithelialization rate. Secondary outcomes encompassed bacterial load reduction and patient compliance.
Results: The phenytoin group demonstrated significantly faster healing with mean time to complete healing of 18.4±4.2 days compared to 26.7±5.8 days in the betadine group (p<0.001). Complete granulation tissue formation occurred in 85% of phenytoin-treated ulcers versus 63.3% in the betadine group (p=0.007). Bacterial load reduction was significantly greater in the phenytoin group (p=0.003), with no significant adverse effects observed in either group.
Conclusion: Topical phenytoin 50mg/ml demonstrated superior efficacy compared to betadine 10% in promoting diabetic foot ulcer healing, with faster granulation tissue formation, epithelialization, and bacterial load reduction. These findings support phenytoin as an effective therapeutic option for diabetic foot ulcer management.
Downloads
Metrics
References
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367-2375.
Yazdanpanah L, Nasiri M, Adarvishi S. Literature review on the management of diabetic foot ulcer. World J Diabetes. 2015;6(1):37-53.
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217-228.
Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005;366(9498):1736-1743.
Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e132-173.
Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care. 1999;22(5):692-695.
Kramer SA. Effect of povidone-iodine on wound healing: a review. J Vasc Nurs. 1999;17(1):17-23.
Shaw J, Hughes CM, Lagan KM, et al. The effect of topical phenytoin on healing in diabetic foot ulcers: a randomized controlled trial. Diabet Med. 2011;28(10):1154-1157.
Tauro LF, Shetty P, Dsouza NT, et al. A comparative study of efficacy of topical phenytoin vs conventional wound care in diabetic ulcers. Int J Mol Med Sci. 2013;3(8):65-71.
Rhodes RS, Heyneman CA, Culbertson VL, et al. Topical phenytoin treatment of stage II decubitus ulcers in the elderly. Ann Pharmacother. 2001;35(6):675-681.
Shaw J, Hughes CM, Lagan KM, et al. The effect of topical phenytoin on healing in diabetic foot ulcers: a randomized controlled trial. Diabet Med. 2011;28(10):1154-1157.
Modaghegh MH, Salehian B, Tavassoli M, et al. Use of phenytoin in healing of war and non-war wounds. A pilot study of 25 cases. Int J Dermatol. 1989;28(5):347-350.
Tauro LF, Shetty P, Dsouza NT, et al. A comparative study of efficacy of topical phenytoin vs conventional wound care in diabetic ulcers. Int J Mol Med Sci. 2013;3(8):65-71.
El-Nahas M, Gawdat HI, Tawfik AA, et al. Phenytoin versus silver sulphadiazine in treatment of diabetic foot ulcers. Egypt J Plast Reconstr Surg. 2009;33(2):187-193.
Lineaweaver W, Howard R, Soucy D, et al. Topical antimicrobial toxicity. Arch Surg. 1985;120(3):267-270.
Zamora JL. Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions. Am J Surg. 1986;151(3):400-406.
Carls GS, Gibson TB, Driver VR, et al. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. J Am Podiatr Med Assoc. 2011;101(2):93-115.
Patil V, Patil R, Kariholu PL, et al. Topical phenytoin application in grade I and II diabetic foot ulcers: a prospective study. J Clin Diagn Res. 2013;7(10):2238-2240.
Pai MR, Sitaraman N, Kotian MS. Topical phenytoin in diabetic ulcers. J Assoc Physicians India. 2001;49:530-531.sky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217-228.
Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005;366(9498):1736-1743.
Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e132-173.
Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care. 1999;22(5):692-695.
Kramer SA. Effect of povidone-iodine on wound healing: a review. J Vasc Nurs. 1999;17(1):17-23.
Shaw J, Hughes CM, Lagan KM, et al. The effect of topical phenytoin on healing in diabetic foot ulcers: a randomized controlled trial. Diabet Med. 2011;28(10):1154-1157.
Tauro LF, Shetty P, Dsouza NT, et al. A comparative study of efficacy of topical phenytoin vs conventional wound care in diabetic ulcers. Int J Mol Med Sci. 2013;3(8):65-71
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
